INNOCARE (09969) surged on heavy volume during afternoon trading. As of press time, the stock was up 12.96% to HK$19 with trading volume reaching HK$406 million.

On the news front, INNOCARE announced on September 8 that Orelabrutinib has received approval from Singapore's Health Sciences Authority (HSA) for the treatment of adult patients with relapsed/refractory marginal zone lymphoma (R/R MZL). This marks the second indication approved for Orelabrutinib in Singapore.

Orelabrutinib has already been approved in China for treating CLL/SLL patients who have received at least one prior treatment, relapsed/refractory mantle cell lymphoma (R/R MCL), and relapsed/refractory marginal zone lymphoma (R/R MZL). All three indications have been included in China's National Health Insurance.

Analysts noted that INNOCARE achieved revenue of 731 million yuan in the first half of 2025, representing a 74.3% year-on-year increase, with core product Orelabrutinib generating sales of 637 million yuan, up 52.8% year-on-year. Orelabrutinib sales continued their strong growth trajectory. During the period, Orelabrutinib's new indication for first-line CLL/SLL treatment received marketing approval and earned a Category 1 recommendation in the 2025 CSCO Lymphoma Guidelines, further expanding Orelabrutinib's market potential in hematologic malignancies and significantly improving market penetration.

Additionally, the company's second innovative drug, Tafasitamab, received marketing approval in May 2025 for combination therapy with lenalidomide in treating relapsed/refractory DLBCL, continuously enriching the commercial product portfolio.